Evkeeza Injection, Solution, Concentrate
NDC Package 61755-010-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Evkeeza (evinacumab) injection is eVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH). This formulation utilizes a injection, solution, concentrate delivery system. Marketed by Regeneron Pharmaceuticals, Inc., this product is identified by NDC 61755-010 and is authorized under FDA application BLA761181.

Identification & Billing

NDC Package Code
61755-010-01
Package Description
1 VIAL, SINGLE-USE in 1 CARTON / 8 mL in 1 VIAL, SINGLE-USE
Product Code
61755-010
11-Digit Billing Format
61755001001
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Evkeeza
Non-Proprietary Name
Evinacumab
Substance Name
Evinacumab
Dosage Form
Injection, Solution, Concentrate - A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
EVINACUMAB 150 mg/mL
Pharmacologic Class
Usage Information
EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).

Regulatory & Marketing

Labeler Name
Regeneron Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761181
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
02-11-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61755-010-01 identifies a specific commercial package of 1 vial, single-use in 1 carton / 8 ml in 1 vial, single-use of Evkeeza, a human prescription drug labeled by Regeneron Pharmaceuticals, Inc.. This injection, solution, concentrate is formulated for intravenous use and contains evinacumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Regeneron Pharmaceuticals, Inc. on February 11, 2021. The current certification is valid through December 31, 2026.

How is this Regeneron Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61755001001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
61755-010-01
11-Digit CMS (5-4-2)
61755-0010-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.